

1 **Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD**  
2 **protein vaccine against COVID-19 in adults: pooled analysis of two randomized,**  
3 **double-blind, placebo-controlled, phase 1 and 2 trials**

4  
5 Shilong Yang\*, Yan Li\*, Lianpan Dai\*, Jianfeng Wang\*, Peng He\*, Changgui Li, Xin  
6 Fang, Chenfei Wang, Xiang Zhao, Enqi Huang, Changwei Wu, Zaixin Zhong, Fengze  
7 Wang, Xiaomin Duan, Siyu Tian, Lili Wu, Yan Liu, Yi Luo, Zhihai Chen, Fangjun Li,  
8 Junhua Li, Xian Yu, Hong Ren, Lihong Liu, Shufang Meng<sup>†</sup>, Jinghua Yan<sup>†</sup>, Zhongyu  
9 Hu<sup>†</sup>, Lidong Gao<sup>†</sup>, George F. Gao<sup>†</sup>

10  
11 Anhui Zhifei Longcom Biopharmaceutical Co. Ltd., HeFei, China (S Yang, E Huang, C  
12 Wu, Z Zhong);

13 CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of  
14 Microbiology, Chinese Academy of Sciences, Beijing, China (Y Li, L Dai, G F Gao);

15 CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of  
16 Microbiology, Chinese Academy of Sciences, Beijing, China (F Wang, X Duan, S Tian,  
17 L Wu, J Yan);

18 National Institute for Food and Drug Control, Beijing, China (J Wang, P He, X Zhao, X  
19 Fang, C Wang, C Li, S Meng, Z Hu);

20 Hunan Provincial Center for Diseases Control and Prevention, Changsha, China (F Li,  
21 J Li, L Gao);

22 The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China (X

23 Yu, H Ren);  
24 Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China (L Liu);  
25 Center of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing,  
26 China (Z Chen);  
27 Beijing Keytech Statistical Technology Co. Ltd., Beijing, China (Y Luo);  
28 Chongqing Medleader Bio-Pharm Co. Ltd., Chongqing, China (Y Liu)

29

30 \* Contributed equally

31 † Correspondence to:

32 George F. Gao, CAS Key Laboratory of Pathogenic Microbiology and Immunology,  
33 Institute of Microbiology, Chinese Academy of Sciences, Beijing 10010, China.  
34 gaof@im.ac.cn

35 or Lidong Gao, Hunan Provincial Center for Diseases Control and Prevention,  
36 Changsha 410005, China. gldlj@hotmail.com

37 or Zhongyu Hu, National Institute for Food and Drug Control, Beijing 100050, China.  
38 huzhy@nifdc.org.cn

39 or Jinghua Yan, CAS Key Laboratory of Microbial Physiological and Metabolic  
40 Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing 10010,  
41 China. yanjh@im.ac.cn

42 or Shufang Meng, National Institute for Food and Drug Control, Beijing 100050, China.  
43 mengsf@263.net

44

45 **Research in context:**

46

47 Evidence before this study

48 We searched for ClinicalTrials.gov and PubMed up to Dec 11, 2020, with the terms  
49 “COVID-19”, “SARS-CoV-2” and “vaccine”. No language restrictions were applied. We  
50 identified 56 vaccine candidates being evaluated in clinical trials, with 12 in phase 3  
51 trials. Thirteen phase 1 and/or phase 2 studies have been published, regarding to 4  
52 inactivated vaccines, 3 adenovirus vectored vaccines, 2 mRNA-based vaccines and 1  
53 protein subunit vaccine. Two phase 3 studies have been published. These vaccines  
54 with published data are mainly targeting either whole virus or spike protein. One RBD-  
55 based vaccine (BNT162b1, developed by BioNTech and Pfizer) was reported using  
56 mRNA expressing RBD-trimer, showing the vaccine is tolerant and immunogenic. The  
57 only published protein subunit vaccine (NVX-CoV2373, developed by Novavax) is  
58 based on modified spike protein with Matrix-M1 as adjuvant. To date, a large number  
59 of RBD-based protein subunit vaccines are under clinical and pre-clinical evaluations  
60 (<http://www.who.int>), but no clinical studies have been published.

61

62 Added value of this study

63 ZF2001 is one of the two protein-based COVID-19 vaccine candidates that  
64 advanced into phase 3 clinical trials but is the first RBD-based protein subunit vaccine  
65 reported for clinical data. Clinical data for protein subunit COVID-19 vaccine using  
66 conventional alum adjuvant was first described here. The phase 1 and phase 2 trials  
67 evaluated the safety profile, immunogenicity, dose-effect and vaccination schedule for

68 ZF2001. This candidate is well-tolerated, without vaccine-related serious adverse  
69 events. Three immunizations at day 0, 30 and 60 achieved 93-100% seroconversion  
70 of neutralizing antibodies, with the GMTs exceeding the magnitude of the convalescent  
71 samples. Also, this vaccine elicited moderate cellular immune responses, detected as  
72 the balanced production of T<sub>H</sub>1/T<sub>H</sub>2 cell-associated cytokines.

73

74 Implications of all the available evidence

75 Our findings indicated that RBD-based protein subunit vaccine is safe and  
76 immunogenic. Further clinical trials should be performed to investigate its protective  
77 efficacy

78

79 **Summary:**

80

81 **Background**

82 A safe and effective coronavirus disease 2019 (COVID-19) vaccine is urgently  
83 needed to control the ongoing pandemic. Although progress has been made recently  
84 with several candidates reporting positive efficacy results, COVID-19 vaccines  
85 developed so far cannot meet the global vaccine demand. We developed a protein  
86 subunit vaccine against COVID-19, using dimeric form of receptor-binding domain  
87 (RBD) as the antigen. We aimed to assess the safety and immunogenicity of this  
88 vaccine in humans and determine the appropriate dose and schedule for an efficacy  
89 study.

90

91 **Methods**

92 We did two randomized, double-blind, placebo-controlled, phase 1 and 2 trials for  
93 an RBD-based protein subunit vaccine, ZF2001. In phase 1 study, 50 healthy adults  
94 aged 18-59 years were enrolled and randomly allocated to three groups to receive  
95 three doses of vaccine (25 µg or 50 µg RBD-dimer, with adjuvant) or placebo (adjuvant-  
96 only) intramuscularly, 30 days apart. In phase 2 study, 900 healthy adults aged 18-59  
97 years were enrolled and randomly allocated to six groups to receive vaccine (25 µg or  
98 50 µg RBD-dimer, with adjuvant) or placebo (adjuvant-only) intramuscularly, with the  
99 former 3 groups given two doses and the latter 3 groups given three doses, 30 days  
100 apart. For phase 1 trial, the primary outcome was safety, as measured by the  
101 occurrence of adverse events and serious adverse events. The secondary outcome  
102 was immunogenicity as measured by the seroconversion rate and magnitude of  
103 antigen-binding antibodies, neutralizing antibodies and T-cell cytokine production. For  
104 phase 2 trial, the primary outcome included both safety and immunogenicity. These  
105 trials are registered with ClinicaTrials.gov, NCT04445194 and NCT04466085.

106

107 **Findings**

108 Between June 22 and September 15, 2020, 50 participants were enrolled to the  
109 phase 1 study (mean age 32.6 years) and 900 participants were enrolled to phase 2  
110 study (mean age 43.5 years), to receive vaccine or placebo with a two-dose or three-  
111 dose schedule. For both trials, local and systemic adverse reactions were absent or

112 mild in most participants. There were no serious adverse events related to vaccine in  
113 either trial. After three doses, neutralizing antibodies were detected in all participants  
114 receiving either 25 µg or 50 µg dose of vaccine in phase 1 study, and in 97% (the 25  
115 µg group) and 93% (the 50 µg group) of participants, respectively, in phase 2 study.  
116 The SARS-CoV-2-neutralizing geometric mean titres (GMTs) were 94.5 for the 25 µg  
117 group and 117.8 for the 50 µg group in phase 1, and 102.5 for the 25 µg group and  
118 69.1 for the 50 µg group in phase 2, exceeding the level of a panel of COVID-19  
119 convalescent samples (GMT, 51). Vaccine induced balanced T<sub>H</sub>1 and T<sub>H</sub>2 responses.  
120 The 50 µg group did not show enhanced immunogenicity compared with the 25 µg  
121 group.

122

### 123 Interpretation

124 The protein subunit vaccine ZF2001 is well-tolerated and immunogenic. The safety  
125 and immunogenicity data from phase 1 and 2 trials for ZF2001 support the use of 25  
126 µg vaccine dose with three-dose schedule to an ongoing phase 3 large-scale  
127 evaluation for safety and efficacy.

128

### 129 Funding

130 National Program on Key Research Project of China, National Science and Technology  
131 Major Projects of Drug Discovery, Strategic Priority Research Program of the Chinese  
132 Academy of Sciences, and Anhui Zhifei Longcom Biopharmaceutical.

133

134 **Introduction:**

135

136 The coronavirus disease in 2019 (COVID-19) pandemic caused by severe acute  
137 respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is still growing worldwide.<sup>1</sup>  
138 As of Dec 11, 2020, over 69 million people have been diagnosed with COVID-19 in  
139 220 countries and regions, with 1.5 million deaths (<http://www.who.int>). To date, no  
140 COVID-19 vaccine has been licensed, although several of them have been approved  
141 for emergency use authorization.<sup>2</sup>

142 Since the COVID-19 pandemic, safe and effective vaccines are highly demanded to  
143 control the disease and reboot the society and economics. After one-year global efforts,  
144 great progresses have been made for COVID-19 vaccine development,<sup>3-17</sup> with several  
145 candidates developed based on mRNA or virus-vector platform announced protective  
146 efficacy more than 70-90% in preventing COVID-19 after an interim analysis.<sup>18-20</sup>  
147 However, these vaccines so far cannot meet the global vaccination demands from  
148 different subpopulations living in different surroundings. Besides, the efficacy duration  
149 and vaccine-related safety concerns are yet to be further determined.<sup>21</sup> An ideal  
150 COVID-19 vaccine should be of high protective efficacy, but safe and deployable for  
151 billions of potential vaccinees. To achieve this goal, optimal vaccine target, platform  
152 and regimen are of high importance.<sup>17</sup> Nowadays, more than 80 vaccines documented  
153 in WHO are based on protein subunit platform, suggesting a major platform for COVID-  
154 19 vaccine development (<http://www.who.int>).

155 To response the pandemic, we launched a vaccine development program against

156 SARS-CoV-2. The resulting vaccine candidate, ZF2001, is one of the two protein  
157 subunit vaccines that has advanced into phase 3 trial (NCT04646590). Compared with  
158 other vaccine candidates in clinical trials targeting mainly whole virus or full-length  
159 spike (S) protein, ZF2001 targets SARS-CoV-2 S protein receptor-binding domain  
160 (RBD). RBD is responsible for the engagement of its cellular receptor human  
161 angiotensin converting enzyme 2 (hACE2) and is an attractive vaccine target to induce  
162 immune responses focusing on blocking the receptor binding.<sup>22-24</sup> We rationally  
163 designed a dimeric form of SARS-CoV-2 RBD with high yields at level of g/L and  
164 dramatically enhanced immunogenicity compared with the conventional monomeric  
165 form of RBD in animal model.<sup>25</sup> ZF2001 is formulated by RBD-dimer protein produced  
166 in Chinese hamster ovary (CHO) cells adjuvanted with aluminum hydroxide.

167 We started the phase 1 trial from June 22, 2020 and phase 2 trial from July 12, 2020  
168 in China for the vaccine candidate ZF2001. Here, we report the pooled analysis of both  
169 trials, in which, vaccine safety and immunogenicity were assessed. Appropriate  
170 vaccine dose and vaccination schedule were determined for efficacy evaluation in  
171 phase 3 trial.

172

### 173 **Methods:**

174

#### 175 Trial design and participants

176 The phase 1 trial was conducted at two hospitals in China: The Second Affiliated  
177 Hospital of Chongqing Medical University (Chongqing) and Beijing Chao-Yang



178 Hospital of Capital Medical University (Beijing). The phase 2 trial was conducted at  
179 Hunan provincial center for disease control and prevention (Xiangtan, China). Eligible  
180 participants were healthy men and nonpregnant women, 18 to 59 years of age. Healthy  
181 status, assessed during the screening period, was based on medical history and  
182 clinical laboratory findings, vital signs, and physical examination. Volunteers who had  
183 a history of SARS or COVID-19, or were tested positive for SARS-CoV-2 exposure (by  
184 real-time PCR assay or enzyme-linked immunosorbent assay [ELISA]), or contacted  
185 with confirmed COVID-19 patients were excluded. Exclusion criteria also included a  
186 history of seizures or mental illness; allergy to any ingredient in the vaccine; acute  
187 febrile disease in 24 hours and digestive diseases in 7 days before enrollment;  
188 congenital or acquired immune diseases; serious chronic disease; abnormal chest CT  
189 image; positive test of HBV, HCV, HIV and syphilis; tumor patients; receipt of any blood  
190 products in the past 3 months; receipt of any research medicines or vaccine in the past  
191 3 month; and being unable to comply with the study schedule. Full details of the  
192 eligibility criteria are described in the trial protocol provided in the appendix.

193 The trial was designed with double-blind, randomized and placebo-parallel-  
194 controlled. Participants in phase 1 were divided into 3 groups at a ratio of 2:2:1 and  
195 allocated to receive three doses of vaccine (25 µg or 50 µg antigen dose) or placebo  
196 on day 0, 30 and 60. Participants in phase 2 were divided into six groups at a  
197 1:1:1:1:1:1 ratio, with the former three groups receiving two doses of vaccine (25 µg or  
198 50 µg antigen dose) or placebo, 30 days apart, while the latter three groups receiving  
199 three doses of vaccine (25 µg or 50 µg antigen dose) or placebo, 30 days apart.

200 Participants were recruited through community recruitment advertisements. All  
201 participants provided written informed consent before enrollment in the trial. The trial  
202 protocol was approved by the institutional review board of The Second Affiliated  
203 Hospital of Chongqing Medical University, Beijing Chao-Yang Hospital of Capital  
204 Medical University, Hunan Provincial Center for Disease Control, Prevention and  
205 National Medical Products Administration (NMPA), China and was performed in  
206 accordance with the Declaration of Helsinki and Good Clinical Practice. Safety  
207 oversight for specific vaccination pause rules and for advancement was performed by  
208 an independent safety monitoring committee.

209

#### 210 Randomisation and masking

211 The randomisation statisticians used SAS statistical software (version 9.4) to  
212 generate the random table of participants in each dose group. These randomisation  
213 statisticians were not allowed to participate in other related work of these clinical trials  
214 and not allowed to disclose the blind code to any personnel participating in this clinical  
215 trial. The participants were randomly assigned to the experimental vaccine group or  
216 the placebo group according to the block randomisation method, with the block and  
217 block size of 5 and 5, respectively, in phase 1 trial, and of 75 and 12, respectively, in  
218 phase 2 trial. Investigators at trial site assign study numbers strictly according to the  
219 order of screening sequence of eligible subjects, and experimental vaccines were  
220 obtained and administered according to the numbers. The participants, field  
221 investigators and laboratory team were always blinded to group allocation during the

222 trial.

223

## 224 Procedures

225 The vaccine was jointly developed by Institute of Microbiology, Chinese Academy of  
226 Sciences and Anhui Zhifei Longcom Biopharmaceutical Co., Ltd.<sup>25</sup> The vaccine was  
227 manufactured according to current Good Manufacturing Practice by Zhifei Longcom  
228 Biopharmaceutical Co., Ltd. The recombinant vaccine encodes the SARS-CoV-2 RBD  
229 antigen (residues 319-537) in dimeric form and was manufactured as a liquid  
230 formulation containing 25 µg or 50 µg per 0.5 mL in a vial, with aluminum hydroxide as  
231 the adjuvant. Vaccines were stored at 2 °C to 8 °C before use. Vaccine or placebo was  
232 administered intramuscularly in the arm of each participant.

233 For both trials, participants were observed in the observation room for 30-60 minutes  
234 after each dose of vaccination for emerging adverse events. During 0-7 days after each  
235 vaccination, any adverse events were self-reported by participants daily on the diary  
236 cards, but verified by investigators. The adverse events during 8-30 days after each  
237 vaccination were reported by participants through contact cards. All serious adverse  
238 events within 1 year after the first dose of vaccination were reported. Solicited local  
239 adverse reactions at injection site within 7 days post-vaccination included pain,  
240 swelling, induration, redness, rash and pruritus and solicited systemic adverse  
241 reactions within 7 days post-vaccination included fever, cough, dyspnea, diarrhea,  
242 anorexia, nausea, vomiting, muscle pain (non-vaccination site), arthritis, joint pain,  
243 headache, fatigue, acute allergic reaction, irritation or inhibition and mental disorder.  
244 Laboratory safety tests including routine blood, and serum chemistry and routine urine

245 were to assess any toxic effects post-vaccination. Adverse events and abnormal  
246 changes in laboratory tests were graded according to the latest scale issued by China  
247 NMPA (Version 2019).

248 The sera were collected to evaluate the binding responses against RBD antigen and  
249 neutralizing activity against live SARS-CoV-2. Peripheral blood mononuclear cells  
250 (PBMC) were collected to assess the specific T cell responses. Blood samples were  
251 taken from participants at the scheduled site visits before the vaccination, on day 14,  
252 30, 37, 60, 67, 90 since first vaccination in phase 1, and on day 14, 30, 44, 60, 74, 90  
253 in phase 2. We used ELISA kits (Wantai BioPharm, Beijing, China) to evaluate the  
254 binding antibody responses against the RBD proteins according to the manufacturer's  
255 protocol. We also assessed the neutralizing activities against live SARS-CoV-2 by  
256 microcytopathogenic effect assay (See Appendix supplementary Methods). PBMCs  
257 from whole blood were isolated and stored in liquid nitrogen in advance, then thawed  
258 before testing. An enzyme-linked immunospot (ELISpot) assay was used to quantify  
259 the specific T-cell responses as previously reported method (See Appendix  
260 supplementary Methods). PBMCs were stimulated with overlapping peptide pools  
261 covering RBD protein for about 20-24 hours before detection, and the number of spot-  
262 forming cells per 1,000,000 cells were calculated. We measured the cytokine secretion  
263 of IFN- $\gamma$ , IL-2, IL-4 and IL-5 with BD™ ELISPOT.

264 A panel of convalescent serum samples with PCR-positive SARS-CoV-2 infection  
265 were obtained from symptomatic hospitalized patients, outpatients and those with  
266 asymptomatic infection detected by health-care worker surveillance. The neutralizing

267 activities of these serum samples against live SARS-CoV-2 were measured by  
268 microcytopathogenic effect assay.

269

## 270 Outcomes

271 For phase 1 trial, primary outcome was the safety of the COVID-19 vaccine.  
272 Secondary outcome was the immunogenicity. For phase 2 trial, primary outcomes were  
273 both safety and immunogenicity.

274 The outcomes for safety were occurrence of the adverse events between first  
275 injection to 30 days after final injection, including all adverse events, adverse events  
276 related to vaccination, adverse events at grade 3 and above, adverse events lead to  
277 participants exit. It also included all serious adverse events occurred between first  
278 injection to 1 year after final vaccination. All adverse events and serious adverse  
279 events related to vaccination were analyzed. Comparison between groups with  
280 different doses and dose regimens were analyzed.

281 The outcomes for immunogenicity were the seroconversion rate and magnitude of  
282 the RBD-binding antibody, SARS-CoV-2 neutralizing antibody and T-cell cytokine  
283 production. Groups with different doses and schedules were compared and analyzed.  
284 Serum samples from vaccine group and the convalescents were compared to assess  
285 and interpret the immunogenicity of the vaccine.

286

## 287 Statistical analysis

288 Based on clinical consideration and recommendation of pilot trial and technical

289 guideline issued by the NMPA in China, the sample sizes for two trials were practical,  
290 and were not determined on a formal statistical power calculation. We firstly compiled  
291 statistics of the number and ratio of participants with adverse reactions or serious  
292 adverse reactions post-vaccination and compared safety difference among the dose  
293 groups using Fisher's exact probability method. The RBD-binding antibodies,  
294 neutralizing titers against live virus were calculated with positive proportion, geometric  
295 mean titres (GMTs). The cytokine production was calculated with GMTs. We used the  
296 Clopper-Pearson method to calculate 95% confidence intervals (CIs),  $\chi^2$  test/Fisher  
297 exact probability method to compare the proportion differences among the dose groups  
298 and Student's t-test to analyze significance of GMTs between different time points.  
299 Statistical analyses were using SAS (version 9.4) and GraphPad Prism (version 8.0.1).

300

301 **Role of the funding source:**

302

303 The funders of the study had no role in data collection, data analysis, data  
304 interpretation, or writing of the Article. All authors had full access to all the data in the  
305 study and had final responsibility for the decision to submit for publication.

306

307 **Results:**

308

309 In phase 1, a total of 107 volunteers were recruited and screened for eligibility  
310 between June 22 and July 3, 2020 in Chongqing and Beijing, China (figure 1). 57

311 individuals were excluded, leaving 50 eligible participants in the trial. They were  
312 randomly divided into 3 groups to receive vaccine (25 µg [n=20] or 50 µg [n=20] RBD-  
313 dimer, with adjuvant) or placebo (adjuvant-only [n=10]). The mean age of all  
314 participants was 32.6 years (SD 9.41; range 20.9-57.9), with balanced age and sex  
315 distribution among vaccination groups (table 1). 8 out of 10 participants in placebo  
316 group, 15 out of 20 participants in the 25 µg group and 18 out of 20 participants in 50  
317 µg group completed three-dose immunization and follow-up visits as schedule (figure  
318 1, appendix 1).

319 In phase 2, a total of 1085 volunteers were recruited and screened for eligibility  
320 between July 12 and July 17, 2020, in Xiangtan, China (figure 1). 185 volunteers were  
321 excluded, and 900 volunteers were enrolled to participate the trial. They were randomly  
322 assigned to 6 groups (n=150) to receive vaccine (25 µg or 50 µg RBD-dimer, with  
323 adjuvant) or placebo (adjuvant-only) with either a two-dose or a three-dose schedule,  
324 30 days apart. The mean age of the participants was 43.5 years (SD 9.17; range 18.8-  
325 59.7) with balanced age and sex distribution among vaccination groups (table 1). All  
326 450 participants with two-dose schedule completed full vaccination and the follow-up  
327 visits. For participants with three-dose schedule, 146 out of 150 participants in placebo  
328 group, 148 out of 150 participants in the 25 µg group and 148 out of 150 participants  
329 in the 50 µg group received full vaccination and completed the follow-up visits (figure  
330 1, appendix 1).

331 For the overall adverse events within 30 days post-vaccination in phase 1 trial, 6  
332 (60%) of 10 participants in the placebo group, 14 (70%) of 20 participants in the 25 µg

333 group and 18 (90%) of 20 participants in the 50 µg group reported at least one adverse  
334 event (figure 2, appendix 2). No statistical significance between these three groups  
335 (P=0.1786). Within 7 days post each vaccination, most of the local and systemic  
336 reactogenicity was absent or mild (grade 1 or 2 adverse events). The most common  
337 solicited local adverse reactions in the placebo, the 25 µg and 50 µg groups were  
338 injection-site pain, reported by 20%, 20% and 55%; redness, reported by 10%, 20%  
339 and 20%; and itch, reported by 0%, 20% and 35%. The most common solicited  
340 systemic adverse reactions in placebo, the 25 µg and 50 µg groups were cough,  
341 reported by 0%, 5% and 15%; fever, reported by 0%, 10% and 0%; and headache,  
342 reported by 0%, 5%, 5% (figure 2, appendix 2). Two grade 3 (or above) adverse events  
343 (10%) were reported in the 50 µg group. One was vaccine-related (swelling and  
344 redness) and the other one was serious adverse event (rhabdomyolysis), but was  
345 vaccine-unrelated as assessed by the investigators (appendix 9). No vaccine-related  
346 serious adverse events or adverse events of special interest were reported.

347 In phase 2 trial, the overall adverse events were low within 30 days after vaccination.  
348 For participants receiving two-dose vaccinations, 37 (25%) in placebo group, 43 (29%)  
349 in the 25 µg group and 50 (33%) in the 50 µg group reported at least one adverse  
350 event. For participants receiving three-dose vaccinations, 47 (31%) in placebo group,  
351 72 (48%) in the 25 µg group and 65 (43%) in the 50 µg group reported at least one  
352 adverse event (figure 2, appendix 3). Within 7 days after each vaccination, most of the  
353 local and systemic reactogenicity was absent or mild (grade 1 or 2 adverse events).  
354 The most common solicited local adverse reactions in placebo, the 25 µg and 50 µg



355 groups were injection-site pain, reported by 4%, 3% and 5% in two-dose participants,  
356 3%, 12% and 12% in three-dose participants; swelling, reported by 1%, 4% and 6% in  
357 two-dose participants, 1%, 14% and 13% in three-dose participants; induration,  
358 reported by 1%, 3% and 5% in two-dose participants, 0%, 9% and 7% in three-dose  
359 participants; redness, reported by 1%, 8% and 8% in two-dose participants, 1%, 16%  
360 and 14% in three-dose participants; and itch, reported by 0%, 6% and 9% in two-dose  
361 participants, 0%, 19% and 17% in three-dose participants. The most common solicited  
362 systemic adverse reactions in the placebo, the 25 µg and 50 µg groups were fever,  
363 reported by 4%, 5% and 7% in two-dose participants, 8%, 8% and 7% in three-dose  
364 participants; cough, reported by 1%, 2% and 2% in two-dose participants, 1%, 1% and  
365 0% in three-dose participants; and headache, reported by reported by 1%, 2% and 1%  
366 in two-dose participants, 0%, 2% and 0% in three-dose participants; and fatigue,  
367 reported by 0%, 3% and 2% in two-dose participants, 3%, 0% and 0% in three-dose  
368 participants (figure 2, appendix 3). 18 participants were reported grade 3 (or above)  
369 adverse events, with 12 of them (1.3%) were vaccine-related, including redness (5  
370 cases), swelling (3 cases), injection-site pain (1 cases), induration (1 case), headache  
371 (1 case) and cough (1 case). Seven participants were reported serious adverse events,  
372 but none of them were considered to related to the study vaccine as assessed by the  
373 investigators (appendix 9). Besides, no adverse events of special interest were  
374 reported.

375       Regarding to the immunogenicity, in phase 1 trial we detected the serologic RBD-  
376 binding IgG titers by ELISA assay to assess the antibody responses. The baseline

377 antibody titres of the participants are shown in the appendix 4. At day 30 after the first  
378 immunization, the seroconversion rates were 61% for the 25 µg group and 79% for the  
379 50 µg group; and were increased to 100% for both groups at day 30 after the second  
380 and third immunizations (figure 3A; appendix 5). At day 30 after the first dose, the  
381 GMTs of vaccine-induced RBD-binding IgG were 23.1 (95% CI, 11.2-47.9) and 40.8  
382 (95% CI, 22.5-74.0) for the 25 µg and 50 µg group, respectively; and were increased  
383 to 1077.0 (95% CI, 663.7-1747.5) and 825.5 (95% CI, 486.9-1399.4) at day 30 after  
384 the second dose; and were further enhanced to 2719.5 (95% CI, 1584.0-4668.8) and  
385 2776.8 (95% CI, 1875.5-4111.2) at day 30 after the third dose (figure 3B; appendix 5).  
386 The GMTs were markedly increased after the second and third doses in both groups.  
387 To analyze the neutralizing antibody titres against live SARS-CoV-2, we measured the  
388 50% neutralizing titres for the serum samples of the participants. The baseline titres of  
389 neutralizing antibodies of the participants are given in the appendix 4. At day 30 after  
390 the second dose, seroconversion rates reached 93.3% in the 25 µg group and 94.4%  
391 in the 50 µg group. At day 7 after the third immunization, the seroconversion rates were  
392 100% in both groups (figure 3C; appendix 6). The SARS-CoV-2-neutralizing GMTs  
393 were 14.0 (95% CI, 8.0-24.6) and 11.4 (95% CI, 6.6-19.8) in the 25 µg and 50 µg group,  
394 respectively, at day 7 after the second dose; and further enhanced to 94.5 (95% CI,  
395 49.3-181.3) and 117.8 (95% CI, 64.6-214.9) in the 25 µg and 50 µg group, respectively,  
396 at day 7 after the third dose (figure 3D; appendix 6). The neutralizing titres dramatically  
397 increased after the second and the third immunizations in both groups. Meanwhile, a  
398 panel of 89 COVID-19 human convalescent serum samples was tested for comparison.

399 The GMT of neutralizing antibodies for the COVID-19 convalescent serum panel was  
400 51 (95% CI, 38.3-70.5). Encouragingly, the neutralizing GMTs for both the 25 µg and  
401 50 µg groups were approximately two times of the magnitude than human  
402 convalescent samples (figure 3D).

403 In phase 2 trial, the baseline antibody titres of the participants are shown in the  
404 appendix 4. At day 30 after the first immunization, the seroconversion rates were 59%  
405 and 65% for the 25 µg and 50 µg group, respectively, in two-dose participants; 63%  
406 and 62% for the 25 µg and 50 µg group, respectively, in three-dose participants. At day  
407 30 after the second immunization, the seroconversion rates were increased to 95%  
408 and 97% for the 25 µg and 50 µg group, respectively, in two-dose participants; 96%  
409 and 94% for the 25 µg and 50 µg, respectively, in three-dose participants. At day 14  
410 after the third immunization, the seroconversion rates were further increased to 99%  
411 and 97% for the 25 µg and 50 µg group, respectively, in three-dose participants (figure  
412 3E; appendix 7). In participants with two-dose schedule, RBD-binding IgG GMTs  
413 significantly increased from 19.4 (95% CI, 16.0-23.6) (30 days after the 1<sup>st</sup>  
414 immunization) to 419.5 (95% CI, 325.8-540.1) (30 days after the 2<sup>nd</sup> immunization) for  
415 the 25 µg group; and from 22.6 (95% CI, 18.5-27.6) (30 days after the 1<sup>st</sup> immunization)  
416 to 344.8 (95% CI, 271.0-438.7) (30 days after the 2<sup>nd</sup> immunization) for the the 50 µg  
417 group (appendix 7). In participants with three-dose schedule, RBD-binding IgG GMTs  
418 significantly increased after each immunization, from 24.4 (95% CI, 19.6-30.2) (30  
419 days after the 1<sup>st</sup> immunization), to 467.3 (95% CI, 366.8-595.3) (30 days after the 2<sup>nd</sup>  
420 immunization), and to 1782.3 (95% CI, 1440.2-2205.7) (14 days after the 3<sup>rd</sup>

421 immunization), for the 25 µg group; and from 22.2 (95% CI, 18.1-27.4) (30 days after  
422 1<sup>st</sup> immunization), to 302.5 (95% CI, 234.2-390.6) (30 days after 2<sup>nd</sup> immunization), to  
423 1140.0 (95% CI, 882.2-1473.2) (14 days after the 3<sup>rd</sup> immunization), for the 50 µg group  
424 (figure 3F; appendix 7). Regarding to the neutralizing antibody titres against live SARS-  
425 CoV-2, seroconversion rates and GMTs were analyzed. For the participants with two-  
426 dose schedule, 76% and 72% were seroconverted in the 25 µg and 50 µg group,  
427 respectively, at 14 days after the 2<sup>nd</sup> immunization (appendix 8). For the participants  
428 with three-dose schedule, 83% and 73% were seroconverted at 14 days after the 2<sup>nd</sup>  
429 immunization in the 25 µg and 50 µg group, respectively; and further increased to 97%  
430 and 93%, respectively, at 14 days after the 3<sup>rd</sup> immunization (figure 3G, appendix 8).  
431 The neutralizing GMT against live SARS-CoV-2 in participants with three-dose  
432 schedule was boosted from 19.5 (95% CI, 15.2-25.0) (14 days after 2<sup>nd</sup> immunization)  
433 to 102.5 (95% CI, 81.8-128.5) (14 days after 3<sup>rd</sup> immunization) in the 25 µg group; and  
434 from 12.6 (95% CI, 10.0-16.0) (14 days after 2<sup>nd</sup> immunization) to 69.1 (95% CI, 53.0-  
435 90.0) (14 days after 3<sup>rd</sup> immunization) in the 50 µg group (figure 3H, appendix 8). After  
436 three-dose vaccination, both the 25 µg and 50 µg groups showed neutralizing GMTs  
437 exceeding the level of a panel of convalescent sera (figure 3H). Again, there is no  
438 enhancement of neutralizing GMT for the participants receiving high vaccine dose (50  
439 µg) compared with those receiving low vaccine dose (25 µg).

440 To assess the T-cell responses, we performed ELISpot assay for the peripheral  
441 blood mononuclear cells (PBMCs) of participants in phase 1 trial against SARS-CoV-  
442 2 RBD protein. T<sub>H</sub>1 and T<sub>H</sub>2 cell responses were measured by detection of the T<sub>H</sub>1

443 cytokines IFN- $\gamma$ , IL-2 and the T<sub>H</sub>2 cytokines IL-4, IL-5. As expected, placebo group did  
444 not show obvious increase for all tested T-cell cytokines. By contrast, either the 25  $\mu$ g  
445 or 50  $\mu$ g group elicited moderate levels of both T<sub>H</sub>1 (IFN- $\gamma$  and IL-2) and T<sub>H</sub>2 (IL-4 and  
446 IL-5) cytokine production post vaccinations (figure 4). Therefore, ZF2001 induced  
447 balanced T<sub>H</sub>1/T<sub>H</sub>2 responses in humans.

448

449 **Discussion:**

450

451 S protein RBD is an attractive vaccine target against coronavirus.<sup>26</sup> To date, a  
452 number of vaccine candidates based on RBD have been demonstrated efficient in  
453 animal models against SARS-CoV, MERS-CoV or SARS-CoV-2.<sup>17</sup> Several RBD-based  
454 COVID-19 vaccines are being evaluated in clinical trials.<sup>17</sup> Clinical data have been  
455 published for an RBD-based COVID-19 vaccine candidate, developed by  
456 BioNTech/Pfizer. This candidate, BNT162b1, is based on mRNA strategy and showed  
457 good immunogenicity in humans.<sup>14,15</sup> Here, we reported the first clinical study for the  
458 RBD-based protein subunit vaccine against coronavirus in a population of 950 health  
459 adult participants.

460 We found vaccination with different doses (25 or 50  $\mu$ g) and schedules (two- or three-  
461 doses) were well-tolerated. The incidents of adverse reactions between vaccine  
462 groups and placebo groups were similar in both phase 1 and 2 trials, without statistical  
463 significance. Most of the adverse reactions were mild, with the most common  
464 symptoms being injection-pain, redness and swelling. These adverse reactions were

465 anticipated for alum-adjuvanted protein subunit vaccines and were transient and  
466 resolved within 3-4 days post-vaccination. Compared with other COVID-19 vaccine  
467 candidates, such as mRNA vaccines or adenovirus-vectored vaccines, the  
468 occurrences of fever and fatigue were lower.<sup>3-7,10,11,13</sup> Compared with another protein  
469 subunit vaccine, NVX-CoV2373, using Matrix-M1 as adjuvant, the occurrences of  
470 injection-site pain, fatigue, headache and nausea were lower, as well.<sup>12</sup>

471 Humoral responses have been considered as immune correlates of protection  
472 against SARS-CoV-2.<sup>27-31</sup> So far, humoral responses for several COVID-19 vaccine  
473 candidates in clinical trials have been reported. It should be noted that currently it is  
474 difficult to compare different vaccine candidates as there are no standardized  
475 neutralization assays. We used microcytopathic effect assay to determine neutralizing  
476 antibody titres for the serum samples from vaccinees, with a panel of COVID-19  
477 convalescent sera tested as the control. The comparative immunogenicity showed  
478 three-dose of ZF2001 elicited neutralizing GMT two times greater than the GMT tested  
479 for the convalescent sera. Notably, two mRNA-based vaccines and two adenovirus-  
480 vectored vaccines have been announced 70-90% efficacy in preventing COVID-19 in  
481 phase 3 clinical trials, with their vaccine-induced humoral responses being reported  
482 similar or higher than those from the convalescent samples.<sup>3-5,13,18</sup> Although the  
483 interpretation of the vaccine immunogenicity can be influenced by the illness severity  
484 of the convalescent selected for comparison, our study indicated encouragingly that  
485 ZF2001 has the potential to elicit protective humoral responses against COVID-19.  
486 Three-dose vaccination was found dramatically enhanced the antibody responses

487 compared with two-dose vaccination, however, increasing the antigen dose from 25  
488 µg to 50 µg did not show an improvement for the immunogenicity. Therefore, vaccine  
489 of 25 µg antigen with three-dose schedule was determined for efficacy evaluation in  
490 phase 3 trial.

491 Cellular immune responses also play protective roles in SARS-CoV-2  
492 infections.<sup>32,33</sup> Virus-specific T-cell responses were associated with milder disease in  
493 COVID-19 patients.<sup>34</sup> Based on the levels of spot-forming cells per million cells,  
494 cytokines representing both T<sub>H</sub>1 and T<sub>H</sub>2 responses were moderately elicited post  
495 vaccination. The moderated but balanced production of T<sub>H</sub>1 and T<sub>H</sub>2 cell-associated  
496 cytokines may benefit for the T-cell-mediated protection rather than the potential risk  
497 of vaccine-enhanced respiratory disease which is presumably caused by predominant  
498 T<sub>H</sub>2-biased responses.<sup>35</sup>

499 This trial report has several limitations. First, the participants in both trials were  
500 young adults aged from 18-59, not including juvenile and elderly persons, whereas,  
501 the elderly is more vulnerable to SARS-CoV-2. Moreover, the participants had limited  
502 ethnic diversity, mainly the ethnic Han. These limitations will be addressed by our  
503 outreach study for cohort covering broader age range and ethnic backgrounds. Second,  
504 the immunogenicity was tested at day 30 post full vaccination in phase 1 and day 14  
505 post full vaccination in phase 2, which cannot be assessed for the duration of the  
506 immune response. Immune responses at later timepoints including those at least 6  
507 months post vaccination will be obtained in the follow-up visits and investigation. Third,  
508 there was still no benchmark to evaluate protective immune responses against COVID-

509 19. Therefore, although ZF2001 induced neutralizing GMTs higher than the  
510 convalescent samples, it is yet hard to predict its protective efficacy. Since no  
511 participant had SARS-CoV-2 exposure, we were unable to assess the protective  
512 efficacy and vaccine-associated enhanced diseases at this moment. This limitation will  
513 be addressed in the ongoing international multi-center phase 3 trials.

514

515 **Contributors:**

516

517 GFG, LD and JY initiated and designed the vaccine. SY, YL (Yan Liu) and JY  
518 contributed to the protocol and design of the trials. XY, HR and LL were the study site  
519 principal investigators in phase 1 trial. FL was the study site principal investigators in  
520 phase 2 trial. LG and JL were responsible for the organization and supervision of the  
521 phase 2 trial. ZZ participated in the implementation of trials. YL (Yan Li), ZH, JY, JW,  
522 PH, CL, SM, XZ, XF, CW, XD, ST, FW and LW were contributed to the laboratory testing  
523 and assay development. ZC was responsible for the collection of convalescent serum  
524 samples. EH and CW were responsible for vaccine manufacture. YL (Yi Luo) did the  
525 statistical analysis. SY, LD, JY and GFG participated in the data collection and analysis  
526 for manuscript. LD, YL (Yan Li) and GFG contributed to the writing of the manuscript.

527

528 **Declaration of interests**

529

530 SY, EH, CW, and ZZ are employees of Anhui Zhifei Longcom Biopharmaceutical Co.



531 Ltd. YL (Yan Liu) is an employee of Chongqing Medleader Bio-Pharm Co. Ltd. YL (Yi  
532 Luo) is an employee of Beijing Keytech Statistical Technology Co. Ltd. LD, YL, JY and  
533 GFG are listed as inventors on pending patent applications for RBD- dimer- based CoV  
534 vaccines. The pending patents for RBD- dimers as protein subunit vaccines for SARS-  
535 CoV-2 have been licensed to Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, China.

536

537 **Data sharing:**

538

539 Individual participant data will be made available on request, directed to the  
540 corresponding author (GFG). After approval of a proposal, data can be shared through  
541 a secure online platform.

542

543 **Acknowledgments:**

544

545 This work is funded by National Program on Key Research Project of China  
546 (2020YFC0842300), National Science and Technology Major Projects of Drug  
547 Discovery (2018ZX09101001), Strategic Priority Research Program of the Chinese  
548 Academy of Sciences (XDB29010202) and Anhui Zhifei Longcom Biopharmaceutical.  
549 We thank Fengcai Zhu, Hudachuan Jiang and Pengfei Jin from Jiangsu Provincial  
550 Center of Disease Control and Prevention (Jiangsu, China) for their valuable help for  
551 the manuscript preparation. We thank Yuhai Bi for providing the virus and the staff of  
552 Biosafety Level 3 Laboratory for their help in live virus experiments (Institute of

553 Microbiology, Chinese Academy of Science) We thank Zhifang Ying and Zhen Chen  
554 for their technical support in neutralization experiments (National Institute for Food and  
555 Drug Control)

556

557 **Figure legends:**

558

559 **Figure 1: Study profile for the phase 1 and phase 2 trials**

560 The reasons why 17 participants (9 in phase 1, and 8 in phase 2) were not included  
561 in the according-to-protocol cohort for vaccination and immunogenicity analysis are  
562 listed in the appendix 1.

563

564 **Figure 2: Solicited and unsolicited adverse events in phase 1 and 2 trials**

565 Adverse events within 7 days post each vaccination and overall adverse events  
566 within 30 days post full vaccination are shown as percentage of participants in each  
567 group. Adverse reactions and events were graded according to the scale issued by  
568 National Medical Products Administration, China. The mild and moderate adverse  
569 events are colored in blue. The grade 3 or above (severe) adverse events are colored  
570 in orange.

571

572 **Figure 3: Humoral immune responses in phase 1 and phase 2 trials**

573 Shown are humoral responses in phase 1 trial (A-D) and phase 2 trial (E-H).  
574 Seroconversion rates (A and E) and geometric mean titres (GMTs) (B and F) of RBD-

575 binding antibody at different time points after vaccination are shown. Seroconversion  
576 rates (C and G) and GMTs (D and H) of neutralizing antibody at different time points  
577 after vaccination are shown. Error bars show 95% confidence intervals (CIs). The  
578 horizontal dashed line indicated the limit of detection. HCS = human convalescent  
579 serum.

580

581

582 **Reference:**

583

- 584 1 Qiang, W. *et al.* Description of the First Strain of 2019-nCoV, C-Tan-nCoV Wuhan Strain  
585 — National Pathogen Resource Center, China, 2020. *China CDC Weekly* 2020; **2**:81-  
586 82.
- 587 2 Mahase, E. Covid-19: UK approves Pfizer and BioNTech vaccine with rollout due to  
588 start next week. *BMJ* 2020; **371**: m4714.
- 589 3 Folegatti, P. M. *et al.* Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine  
590 against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised  
591 controlled trial. *Lancet* 2020; **396**: 467-478.
- 592 4 Logunov, D. Y. *et al.* Safety and immunogenicity of an rAd26 and rAd5 vector-based  
593 heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-  
594 randomised phase 1/2 studies from Russia. *Lancet* 2020; **396**: 887-897.
- 595 5 Ramasamy, M. N. *et al.* Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine  
596 administered in a prime-boost regimen in young and old adults (COV002): a single-  
597 blind, randomised, controlled, phase 2/3 trial. *Lancet*, 2020; **396**:1979-1993.
- 598 6 Zhu, F. C. *et al.* Immunogenicity and safety of a recombinant adenovirus type-5-  
599 vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised,  
600 double-blind, placebo-controlled, phase 2 trial. *Lancet* 2020; **396**: 479-488.
- 601 7 Zhu, F. C. *et al.* Safety, tolerability, and immunogenicity of a recombinant adenovirus  
602 type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised,  
603 first-in-human trial. *Lancet* 2020; **395**: 1845-1854.
- 604 8 Xia, S. *et al.* Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine,  
605 BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. *Lancet*  
606 *Infect Dis* 2020; published on line Oct 17. doi:10.1016/S1473-3099(20)30831-8.
- 607 9 Zhang, Y. *et al.* Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2  
608 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-  
609 controlled, phase 1/2 clinical trial. *Lancet Infect Dis* 2020; published on line Nov 17.  
610 doi:10.1016/S1473-3099(20)30843-4.
- 611 10 Anderson, E. J. *et al.* Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine  
612 in Older Adults. *N Engl J Med* 2020; **383**: 2427-2438.
- 613 11 Jackson, L. A. *et al.* An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. *N*  
614 *Engl J Med* 2020 **383**:1920-1931.
- 615 12 Keech, C. *et al.* Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein  
616 Nanoparticle Vaccine. *N Engl J Med* 2020; **383**: 2320-2332.
- 617 13 Walsh, E. E. *et al.* Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine  
618 Candidates. *N Engl J Med* 2020; **383**: 2439-2450.
- 619 14 Mulligan, M. J. *et al.* Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults.  
620 *Nature* 2020; **586**: 589-593.
- 621 15 Sahin, U. *et al.* COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell  
622 responses. *Nature* 2020; **586**: 594-599.
- 623 16 Xia, S. *et al.* Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and

624 Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. *JAMA*  
625 2020; **324**: 951-960.

626 17 Dai, L. & Gao, G. F. Viral targets for vaccines against COVID-19. *Nature Reviews*  
627 *Immunology* 2020; publish online Dec 8. doi:10.1038/s41577-020-00480-0.

628 18 Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N*  
629 *Engl J Med* 2020; publish online Dec 10. doi:10.1056/NEJMoa2034577.

630 19 Voysey, M. *et al.* Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222)  
631 against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil,  
632 South Africa, and the UK. *Lancet* 2020; publish online Dec 8. doi:10.1016/S0140-  
633 6736(20)32661-1.

634 20 Mahase, E. Covid-19: Moderna applies for US and EU approval as vaccine trial reports  
635 94.1% efficacy. *BMJ* 2020; **371**, m4709

636 21 Moore, J. P. & Klasse, P. J. COVID-19 Vaccines: "Warp Speed" Needs Mind Melds, Not  
637 Warped Minds. *J Virol* 2020; **94**: e01083-20.

638 22 Premkumar, L. *et al.* The receptor binding domain of the viral spike protein is an  
639 immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. *Sci*  
640 *Immunol* 2020; **5**: eabc8413.

641 23 Wang, N., Shang, J., Jiang, S. & Du, L. Subunit Vaccines Against Emerging Pathogenic  
642 Human Coronaviruses. *Front Microbiol* 2020; **11**: 298.

643 24 Wang, Q. *et al.* Structural and Functional Basis of SARS-CoV-2 Entry by Using Human  
644 ACE2. *Cell* 2020; **181**: 894-904.

645 25 Dai, L. *et al.* A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS,  
646 and SARS. *Cell* 2020; **182**: 722-733

647 26 Lu, G., Wang, Q. & Gao, G. F. Bat-to-human: spike features determining 'host jump' of  
648 coronaviruses SARS-CoV, MERS-CoV, and beyond. *Trends Microbiol* 2015; **23**: 468-  
649 478.

650 27 Yu, J. *et al.* DNA vaccine protection against SARS-CoV-2 in rhesus macaques. *Science*  
651 2020; **369**: 806-811.

652 28 Addetia, A. *et al.* Neutralizing Antibodies Correlate with Protection from SARS-CoV-2  
653 in Humans during a Fishery Vessel Outbreak with a High Attack Rate. *J Clin Microbiol*  
654 2020; **58**: e02107-20

655 29 Mercado, N. B. *et al.* Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus  
656 macaques. *Nature* 2020; **586**: 583-588.

657 30 Gao, Q. *et al.* Development of an inactivated vaccine candidate for SARS-CoV-2.  
658 *Science* 2020; **369**: 77-81.

659 31 Wang, H. *et al.* Development of an Inactivated Vaccine Candidate, BBIBP-CoV, with  
660 Potent Protection against SARS-CoV-2. *Cell* 2020; **182**: 713-721.

661 32 Sun, J. *et al.* Generation of a Broadly Useful Model for COVID-19 Pathogenesis,  
662 Vaccination, and Treatment. *Cell* 2020; **182**: 734-743.

663 33 Liu, W. J. *et al.* T-cell immunity of SARS-CoV: Implications for vaccine development  
664 against MERS-CoV. *Antiviral Res* 2017; **137**: 82-92.

665 34 Sekine, T. *et al.* Robust T Cell Immunity in Convalescent Individuals with Asymptomatic  
666 or Mild COVID-19. *Cell* 2020; **183**: 158-168.

667 35 Su, S., Du, L. & Jiang, S. Learning from the past: development of safe and effective

668 COVID-19 vaccines. *Nat Rev Microbiol*, 2020; publish online Oct 16.  
669 doi:10.1038/s41579-020-00462-y.

670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711

712 **Table 1: Baseline demographic characteristics of participants in phase 1 and phase 2**  
 713 **trials**

	Cohort in phase 1			Cohort in phase 2					
	Placebo, 3-dose (n=10)	25 µg, 3-dose (n=20)	50 µg, 3-dose (n=20)	Placebo, 2-dose (n=150)	25 µg, 2-dose (n=150)	50 µg, 2-dose (n=150)	Placebo, 3-dose (n=150)	25 µg, 3- dose (n=150)	50 µg, 3-dose (n=150)
<b>Ages, (year)</b>									
Mean (SD)	32.5 (11.3)	31.7 (9.7)	33.6 (8.5)	44.1 (9.3)	43.04 (9.6)	44.4 (8.4)	43.4 (8.9)	42.7 (9.4)	43.2 (9.4)
Median	29.4	26.7	34.1	46.1	43.7	45.3	44.4	43.7	43.7
Min, Max	21.0, 57.9	22.9, 54.7	20.9, 49.4	20.7, 59.4	18.8, 58.4	19.9, 59.1	20.7, 58.0	20.0, 59.7	19.3, 59.6
<b>Ethnic group</b>									
Chinese Han nationality	9 (90%)	20 (100%)	18 (90%)	149 (99%)	150 (100%)	150 (100%)	149 (99%)	150 (100%)	148 (99%)
Others	1 (10%)	0	2 (10%)	1 (1%)	0	0	1 (1%)	0	2 (1%)
<b>Sex</b>									
Male	5 (50%)	14 (70%)	11 (55%)	68 (45%)	65 (43%)	57 (38%)	74 (49%)	71 (47%)	63 (42%)
Female	5 (50%)	6 (30%)	9 (45%)	82 (55%)	85 (57%)	93 (62%)	76 (51%)	79 (53%)	87 (58%)

714  
 715 Data are mean (SD) or n (%)  
 716

717

718

719


720

721


722

723


**Phase 1 trial**



**Phase 2 trial**









731  
732

Figure 3



733  
734  
735  
736  
737  
738  
739  
740  
741  
742

743 Figure 4  
744



745